NCT01696942View on ClinicalTrials.gov

Cimzia Versus Mesalamine for Crohn's Recurrence

PHASE4TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Crohn's Disease
Interventions
DRUG

Cimzia

400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks

DRUG

Mesalamine

mesalamine 800 mg orally three times daily

Trial Locations (1)

17033

Penn State Milton S. Hershey Medical Center, Hershey

Sponsors

Collaborators (1)

UCB Pharma
All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Milton S. Hershey Medical Center

OTHER